Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women

References

• Luscher T F, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20(11 Suppl 2)II-3–10
   Web of Science ®Google Scholar
• Stankevicius E, Kevelaitis E, Vainorius E, Simonsen U. Role of nitric oxide and other endothelium-derived factors. Medicina (Kaunas) 2003; 39: 333–341
   PubMedGoogle Scholar
• Brunner H, Cockcroft J R, Deanfield J, et al. Endothelial function and dysfunction. II. Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233–246
   PubMed Web of Science ®Google Scholar
• Corretti M C, Anderson T J, Benjamin E J, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 16: 257–265
   Google Scholar
• Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. 2. Altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001; 27: 436–447
   PubMed Web of Science ®Google Scholar
• Fabian E, Varga A, Picano E, Vajo Z, Ronaszeki A, Csanady M. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol 2004; 94: 652–655
   PubMed Web of Science ®Google Scholar
• Nawaz H, Katz D L. American College of Preventive Medicine Practice Policy Statement: Perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med 1999; 17: 250–254
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847–857
   PubMed Web of Science ®Google Scholar
• Walsh B W. The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors. Ann N Y Acad Sci 2001; 949: 163–17
   PubMed Web of Science ®Google Scholar
• Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena M G. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol 2004; 44: 1636–1640
   PubMed Web of Science ®Google Scholar
• Collins P, Rosano G M, Sarrel P M, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92: 24–30
   PubMed Web of Science ®Google Scholar
• Silvestri A, Gambacciani M, Vitale C, et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005; 50: 305–311
   PubMed Web of Science ®Google Scholar
• Chen D B, Bird I M, Zheng J, Magness R R. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 2004; 145: 113–125
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Wenger N K. Menopausal hormone therapy: currently no evidence for cardiac protection. Pediatr Blood Cancer 2005; 44: 625–629
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Upmalis D H, Lobo R, Bradley L, Warren M, Cone F L, Lamia C A. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo- controlled study. Menopause 2000; 7: 236–342
   PubMed Web of Science ®Google Scholar
• Han K K, Soares J M, Jr, Haidar M A, de Lima G R, Baracat E C. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99: 389–394
   PubMed Web of Science ®Google Scholar
• Simons L A, von Konigsmark M, Simons J, Celermajer D S. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 2000; 85: 1297–1301
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani A R. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000; 85: 2966–2969
   PubMed Web of Science ®Google Scholar
• Figtree G, Ying-qing, Webb C, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999; 100: 1095–1101
   PubMed Web of Science ®Google Scholar
• Zoma W, Baker R, Clark K. Coronary and uterine vascular resonses to raloxifene in the sheep. Am J Obstet Gynecol 2000; 182: 521–528
   PubMed Web of Science ®Google Scholar
• Figtree G A, Webb C M, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther 2000; 295: 519–523
   PubMed Web of Science ®Google Scholar
• Seely E W, Brosnihan K B, Jeunemaitre X, et al. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinol (Oxf) 2004; 60: 315–321
   PubMed Web of Science ®Google Scholar
• Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512–1519
   PubMed Web of Science ®Google Scholar
• Sarrel P M, Nawaz H, Chan W, Fuchs M, Katz D L. Raloxifene enhances endothelial function in healthy post-menopausal women. Am J Obstet Gynecol 2003; 188: 304–309
   PubMed Web of Science ®Google Scholar
• Cerquetani E, Mercuro G, Fini M, et al. Hormone replacement therapy but not raloxifene improves endothelial function in postmenopausal women with increased cardiovascular risk. Paper presented at 12th Annual Meeting of the North American Menopause Society, New Orleans, October, 4–62001
   Google Scholar
• Katz D L, Evans M, Nawaz H, et al. Egg consumption & endothelial function in healthy adults: A randomized controlled crossover trial. Int J Cardiol 2005; 99: 65–70
   PubMed Web of Science ®Google Scholar
• Mosca L, Barrett-Connor E, Wenger N K, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001; 88: 392–395
   PubMed Web of Science ®Google Scholar
• Blum A, Hathaway L, Mincemoyer R, et al. Hormonal, lipoprotein, and vascular effects of the selective estrogen receptor modulator raloxifene in hypercholesterolemic men. Am J Cardiol 2000; 85: 1491–1494, A1497
   PubMed Web of Science ®Google Scholar
• Anderson P W, Cox D A, Sashegyi A, Paul S, Silfen S L, Walsh B W. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 2001; 39: 71–77
   PubMed Web of Science ®Google Scholar
• Jolly E E, Bjarnason N H, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10: 337–344
   PubMed Web of Science ®Google Scholar
• Vogel R A. Measurement of endothelial function by brachial artery flow-mediated vasodilation. Am J Cardiol 2001; 88(Suppl)31–4E
   Google Scholar
• Teede H J, Dalais F S, Kotsopoulos D, Liang Y L, Davis S, McGrath B P. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 2001; 86: 3053–3060
   PubMed Web of Science ®Google Scholar
• Dewell A, Hollenbeck C B, Bruce B. The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 2002; 87: 118–121
   PubMed Web of Science ®Google Scholar
• Gardner C D, Newell K A, Cherin R, Haskell W L. The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women. Am J Clin Nutr 2001; 73: 728–735
   PubMed Web of Science ®Google Scholar
• Puska P, Korpelainen V, Hoie L H, Skovlund E, Lahti T, Smerud K T. Soy in hypercholesterolaemia: a double-blind, placebo-controlled trial. Eur J Clin Nutr 2002; 56: 352–357
   PubMed Web of Science ®Google Scholar
• Jenkins D J, Kendall C W, Jackson C J, et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr 2002; 76: 365–372
   PubMed Web of Science ®Google Scholar
• De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001; 184: 350–353
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Jayagopal V, Kilpatrick E S, Chapman T, Atkin S L. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes. Diabetes Care 2007; 30: 1871–1873
   PubMed Web of Science ®Google Scholar
• Jayagopal V, Albertazzi P, Kilpatrick E S, et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 2002; 25: 1709–1714
   PubMed Web of Science ®Google Scholar
• Lee S J, Lee D W, Kim K S, Lee I K. Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes. Diabetes Res Clin Pract 2001; 54(Suppl 20)S81–92
   PubMedGoogle Scholar
• Clarkson T B. Stage of atherogenesis and effectiveness of ERT/HRT. Paper presented at The North American Menopause Society 13th Annual Meeting, Chicago, October, 42002
   Google Scholar
• Barrett-Connor E, Cox D, Anderson P. The potential of SERMs for reducing the risk of coronary heart disease. TEM 1999; 10: 320–325
   PubMed Web of Science ®Google Scholar
• Low A K, Russell L D, Holman H E, Shepherd J M, Hicks G S, Brown C A. Hormone replacement therapy and coronary heart disease in women: a review of the evidence. Am J Med Sci 2002; 324: 180–184
   PubMed Web of Science ®Google Scholar